Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.34 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804163 | 0.79 | P2RX3 (0.47) | P2RX3KCNJ5KCNJ3CA2 | |
| SCHEMBL12800784 | 0.77 | NPC1 (0.45) | — | |
| SCHEMBL945863 | 0.77 | P2RX3 (0.41) | P2RX3KCNJ5KCNJ3CA2MAPK14 | |
| SCHEMBL944361 | 0.77 | P2RX3 (0.41) | P2RX3KCNJ5KCNJ3CA2MAPK14 | |
| SCHEMBL23374815 | 0.77 | P2RX3 (0.41) | P2RX3KCNJ5KCNJ3CA2MAPK14 | |
| SCHEMBL13125279 | 0.76 | MRGPRX4 (0.46) | P2RX3KCNJ5KCNJ3 | |
| SCHEMBL2503804 | 0.73 | CA2 (0.40) | P2RX3KCNJ5KCNJ3CA2MAPK14 | |
| SCHEMBL2503801 | 0.73 | CA2 (0.40) | P2RX3KCNJ5KCNJ3CA2MAPK14 | |
| SCHEMBL13125239 | 0.73 | HTR7 (0.44) | P2RX3KCNJ5KCNJ3CA2 | |
| SCHEMBL12519657 | 0.72 | CA2 (0.42) | P2RX3KCNJ5KCNJ3CA2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338429-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-2314586-A1 | 2-Acylaminothiazole derivative or salt thereof | Astellas Pharma Inc. (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-7638536-B2 | N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally | ASTELLAS PHARMA INC. (JP) | 2009-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222329-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | P2RX3 3334/4885KCNJ5 2628/4885KCNJ3 1342/4885 |
| US-20100222361-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | P2RX3 3334/4885KCNJ5 2628/4885KCNJ3 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.